SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

For the first time ever, the board that disciplines attorneys is recommending a former Massachusetts prosecutor lose her law license for failing to turn over evidence that might have exonerated ...

- The first patient has been dosed in the ONKORAS-101 trial for the study of BBO-8520 in adult subjects with KRAS G12C non-small cell lung cancer - BBO-8520 is a first-in-class orally bioavailable and ...

BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger that ...

PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Researchers from Bridgebio Pharma Inc. presented preclinical characterization of the novel next-generation KRAS G12C GTP/GDP dual inhibitor candidate, BBO-8520, being developed for the treatment of ...

Beta-Barium Borate (BBO) is a nonlinear crystal characterised by a broad phase-matchable range from 409.6nm to 3500nm, a wide transmission region from 190nm to 3500nm and a high laser damage threshold ...

Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without ...

Ultrathin BBO crystals of thickness down to 10 microns with protective hard (IBS) AR coating are available. EKSMA OPTICS offers BBO crystals of thickness down to 10 microns for frequency conversion of ...

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in patients with KRAS mutant pancreatic, non-small cell lung, and colorectal cancer with initial Phase 1 clinical data expected ...